ArticleThe Journal of infectious diseases2013
Immune response to hepatitis B virus vaccination among HIV-1 infected and uninfected adults in Kenya.
Article in The Journal of infectious diseases, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 2 syntheses or guidelines pooled it, 53 citations in OpenAlex.
- The burden of Hepatitis B virus infection in Kenya: A systematic review and meta-analysis.Frontiers in public health · 2023Pooled it
- Efficacy and safety of human papillomavirus vaccination in HIV-infected patients: a systematic review and meta-analysis.Scientific reports · 2021Pooled it
- Higher rate of long-term serologic response of four double doses vs. standard doses of hepatitis B vaccination in HIV-infected adults: 4-year follow-up of a randomised controlled trial.AIDS research and therapy · 2019Trial
- Review
- Article
- Immune response to hepatitis B vaccine among children under 5 years in Africa: a meta-analysis.Tropical medicine and health · 2024Review
- Undetectable Anti-HBs Antibodies: Need of a Booster Dose for HIV-1-Infected Individuals.Vaccines · 2021Review
- Article
- The role of hepatitis B vaccine challenge dose in patients with underlying health conditions.Human vaccines & immunotherapeutics · 2021Article
- Occult hepatitis B virus infection in a Kenyan cohort of HIV infected anti-retroviral therapy naïve adults.PloS one · 2021Article
- Addressing the global burden of hepatitis B virus while developing long-acting injectables for the prevention and treatment of HIV.The lancet. HIV · 2020Review
- HPV vaccination in HIV infection.Papillomavirus research (Amsterdam, Netherlands) · 2019Review
- Hepatitis B Vaccination and Waning Hepatitis B Immunity in Persons Living with HIV.Current HIV/AIDS reports · 2019Review
- Post Hepatitis B vaccination sero-conversion among health care workers in the Cape Coast Metropolis of Ghana.PloS one · 2019Article
- Short-term immunogenicity of standard and accelerated hepatitis B virus vaccination schedules in healthy adults: a comparative field study in China.Bioscience reports · 2018Article
- Efficacy of Hepatitis B Vaccination among Children in Special Region of Yogyakarta, Indonesia: Evaluation of Humoral and Cellular Immunity.The Kobe journal of medical sciences · 2018Article
- Vaccinations for the HIV-Infected Adult: A Review of the Current Recommendations, Part I.Infectious diseases and therapy · 2017Review
- Hepatitis B virus vaccination in HIV-infected people: A review.Human vaccines & immunotherapeutics · 2017Review
- Response to hepatitis B vaccination among HIV-infected adults in Vietnam.Journal of virus eradication · 2016Article
- Hepatitis B virus burden in developing countries.World journal of gastroenterology · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 2 countries.
Funding
Abstract
backgroundIn studies from high-income countries, human immunodeficiency virus type 1 (HIV-1)-infected persons have diminished responses to hepatitis B virus (HBV) vaccination, compared with HIV-1-uninfected persons, but data from other settings are limited.
methodsWe compared the immune response to HBV vaccination among HIV-1-infected and HIV-1-uninfected Kenyan adults and assessed the response of HIV-1-infected initial nonresponders to revaccination with a standard HBV vaccine series.
resultsOf 603 participants, 310 (51.4%) were HIV-1-infected, for whom the median CD4(+) T-cell count was 557 cells/μL (interquartile range, 428-725 cells/μL); none were receiving antiretroviral therapy. Nonresponse to HBV vaccine was higher among HIV-1-infected participants, compared with HIV-1-uninfected participants (35.8% vs 14.3%; odds ratio, 3.33; P < .001). Of 102 HIV-1-infected initial nonresponders, 88 (86.3%) responded to revaccination, for an overall response, including to revaccination, of 94.9%. Among HIV-1-infected individuals, lower CD4(+) T-cell counts and male sex were independent predictors of nonresponse to initial vaccination, and lower body mass index, higher plasma HIV-1 RNA levels, and longer time to revaccination predicted nonresponse to revaccination.
conclusionsKenyan adults had similar HBV vaccination responses as persons from high-income countries. Timely revaccination of HIV-1-infected nonresponders increased response to the vaccine to 95%.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.